The Commonwealth Serum Laboratories was established in Australia in 1916.
At CSL, Corporate Responsibility is about conducting our business ethically.
We offer the broadest range of quality plasma-derived and recombinant therapies in the industry.
Seqirus opened in 2015 and is the second largest influenza company in the world.
Innovation has been in the DNA of CSL since our beginning in 1916
Our product portfolio focuses on innovation in new products
Our interim dividend for 2021 is US$1.04, an increase of 9%
Our exceptionally strong performance is a result of the focused execution of our strategy.
Help us deliver on our promise to save lives and protect the health of people.
Diversity and inclusion are top priorities for CSL.
View our ASX announcements
Visit this page to see all of our current news releases
Update on the UQ COVID-19 vaccine
University of Oxford/AstraZeneca Vaccine Candidate
CSL Commences Manufacturing of University of Oxford/AstraZeneca Vaccine Candidate in Melbourne.
CSL Named as One of the World’s Best Employers
Forbes Recognizes Global Biotechnology Leader for Fourth Straight Year
CSL's Annual Research and Development Day Briefing
2021 CSL Centenary Fellowships Announced
First Patient Enrolled in NIH Phase 3 Trial to Evaluate Potential COVID-19 Hyperimmune Medicine
Agreement to supply 51 mil vaccine doses
Joy Linton named as Chief Financial Officer
CSL has appointed Ms Joy Linton, a well-respected global leader with extensive strategic and financial experience as Chief Fi…
CSL to manufacture and supply vaccine candidates
Popular search terms:
Americas
Asia Pacific
Europe
This website uses cookies to improve user experience. By continuing to use this website, you consent to our use of these cookies. To learn more about how we use and manage cookies, see our Privacy Policy and Cookie Policy.
